Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

DOI
Publisher DOI
PubMed ID
30514803
Abstract
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800mg (high-dose) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can be safely performed without increasing the risk of losing deep molecular response is unknown. To gain insights into this clinically relevant question, we analyzed the outcome of imatinib dose reductions from 800mg to 400mg daily in the Chronic Myeloid Leukemia-Study IV. Of the 422 patients that were randomized to the 800mg arm, 68 reduced imatinib to 400mg after they had achieved at least a stable major molecular response. 61 of these 68 patients (90%) maintained major molecular remission on imatinib at 400mg. Five of the seven patients, who lost major molecular remission on the imatinib standard dose, regained major molecular remission while still on 400mg imatinib. Only two of 68 patients had to switch to more potent kinase inhibition to regain major molecular remission. Importantly, the lengths of the imatinib high-dose treatment intervals before and after achieving major molecular remission were associated with the probabilities of maintaining major molecular remission with the standard dose of imatinib. Together, data support that a deep molecular remission achieved with high-dose imatinib, can be safely maintained with standard dose in most patients. The study protocol was registered at ClinicalTrials.gov (NCT00055874).
Date Issued
2019-05
Publication Type
Article
Subject(s)
Subjects
CML study IV Chronic Myelogenous Leukemia dose reduction imatinib safety
Language(s)
en
Author(s)
Michel, Christian
Burchert, Andreas
Hochhaus, Andreas
Saussele, Susanne
Neubauer, Andreas
Lauseker, Michael
Krause, Stefan W
Kolb, Hans-Jochem
Hossfeld, Dieter Kurt
Nerl, Christoph
Baerlocher, Gabriela M.
Heim, Dominik
Brümmendorf, Tim H
Fabarius, Alice
Haferlach, Claudia
Schlegelberger, Brigitte
Balleisen, Leopold
Goebeler, Maria-Elisabeth
Hänel, Mathias
Ho, Anthony
Dengler, Jolanta
Falge, Christiane
Möhle, Robert
Kremers, Stephan
Kneba, Michael
Stegelmann, Frank
Köhne, Claus-Henning
Lindemann, Hans-Walter
Waller, Cornelius F
Spiekermann, Karsten
Berdel, Wolfgang E
Müller, Lothar
Edinger, Matthias
Mayer, Jiri
Beelen, Dietrich W
Bentz, Martin
Link, Hartmut
Hertenstein, Bernd
Fuchs, Roland
Wernli, Martin
Schlegel, Frank
Schlag, Rudolf
de Wit, Maike
Trümper, Lorenz
Hebart, Holger
Hahn, Markus
Thomalla, Jörg
Scheid, Christof
Schafhausen, Philippe
Verbeek, Walter
Eckart, Michael J
Gassmann, Winfried
Schenk, Michael
Brossart, Peter
Wündisch, Thomas
Geer, Thomas
Bildat, Stephan
Schäfer, Erhardt
Hasford, Joerg
Hehlmann, Rüdiger
Pfirrmann, Markus
Additional Credits
Journal
Haematologica - the hematology journal
Publisher
Ferrata-Storti Foundation
ISSN
0390-6078
Access(Rights)
restricted
Show full item